Via binding to the 3′-UTRs of FOS-like 2 (FOSL2), miR-143 can negatively regulate FOSL2 expression, suggesting that the UCA1/miR-143 axis may have potential therapeutic value for the treatment of cisplatin resistance in ovarian cancer patients (Li Z. et al., 2019). This evidence concerns the gene FOSL2 and ovarian carcinoma.